Xopenex HFA (Levalbuterol Tartrate Inhalation Aerosol) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Xopenex HFA

Asthma Complexities »

Unusual symptoms of asthma

Patients suffering from episodes of asthma do not always have the typical symptoms of asthma such as shortness of breath, chest tightness, and wheezing (symptoms of airway narrowing). Instead, patients can have symptoms that may not appear to be related to asthma. These "unusual" asthma symptoms include

rapid breathing,
sighing,
fatigue and inability to exercise properly,
difficulty sleeping,
anxiety and difficulty concentrating,
chronic cough without wheezing,
protracted cough after an upper respiratory illness,
recurrent diagnosis of walking pneumonia, and
noises emanating from the chest usual during exhalation.

To complicate matters, symptoms of asthma are not consistent and often vary from time to time in an individual. In some patients, symptoms are influenced by diurnal factor...

Read the Asthma Complexities article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Xopenex HFA User Reviews >>

Xopenex HFA

Asthma Slideshow Pictures

Take the Asthma Quiz!

10 Worst Cities for Asthma Slideshow Pictures

font size

OVERDOSE

The expected symptoms with overdosage are those of excessive beta-adrenergic receptor stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and sleeplessness. Hypokalemia also may occur. As with all sympathomimetic medications, cardiac arrest and even death may be associated with the abuse of XOPENEX HFA (levalbuterol tartrate inhalation aerosol) (levalbuterol tartrate) Inhalation Aerosol. Treatment consists of discontinuation of XOPENEX HFA Inhalation Aerosol together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of XOPENEX HFA (levalbuterol tartrate inhalation aerosol) Inhalation Aerosol.

Following intravenous administration in mice, the median lethal levalbuterol HCl dose was approximately 66 mg/kg (approximately 500 times the maximum recommended daily inhalation dose of levalbuterol tartrate for adults on a mg/m² basis and approximately 230 times the maximum recommended daily inhalation dose of levalbuterol tartrate for pediatric patients on a mg/m² basis). Following intravenous administration in rats, the median lethal levalbuterol HCl dose was approximately 60 mg/kg (approximately 900 times the maximum recommended daily inhalation dose of levalbuterol tartrate for adults on a mg/m² basis and approximately 430 times the maximum recommended daily inhalation dose of levalbuterol tartrate for children on a mg/m² basis). The inhalation median lethal dose has not been determined in animals. In dogs, inhaled doses of levalbuterol HCl up to 2.73 mg/kg (approximately 140 times the maximum recommended daily inhalation dose of levalbuterol tartrate for adults on a mg/m² basis and approximately 65 times the maximum recommended daily inhalation dose of levalbuterol tartrate for children on a mg/m² basis) were tolerated without animal deaths.

CONTRAINDICATIONS

XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol is contraindicated in patients with a history of hypersensitivity to levalbuterol, racemic albuterol, or any other component of XOPENEX HFA (levalbuterol tartrate inhalation aerosol) Inhalation Aerosol.

Last reviewed on RxList: 3/6/2008
This monograph has been modified to include the generic and brand name in many instances.